Ionis Pharmaceuticals, Inc. (NASDAQ:IONS) has seen its stock price gain 3.55, or -7.06%, so far in 2017. In the past 3-month period alone, shares of IONS have appreciated -8.37 – or -15.19%. The stock’s 52-week range is $37.26 to $65.51, and its 3-month range is $44.41 to $57.92.
The average Wall Street analyst rating for Ionis Pharmaceuticals, Inc. is Hold, according to the average of 10 analyst scores. Of those analysts, 3 rate stock as a Strong Buy, 6 rate it as Hold, and just 1 analyst rates it as a Moderate Sell.Insider Trading Activity for Ionis Pharmaceuticals, Inc.
Examining insider trading at Ionis Pharmaceuticals, Inc. (NASDAQ:IONS) can provide us with excellent insight into how the company’s stock is performing. Ionis Pharmaceuticals, Inc. has had 34 insider trades in the last 3 months, including 7 open market buys and 27 sells. Of those insider trades, 1,312 shares of Ionis Pharmaceuticals, Inc. were purchased and 112,805 shares were sold. The total number of shares traded in the last 90-day period is 114,117.
Insider trading over the last 12 months, however, paints a different picture. In the last year there have been a total of 80 insider trades, including 14 open market buys and 66 sells. Of those transactions, there were 2,269 shares of IONS bought and 332,695 shares sold. The total number of shares traded in the last 12 months is 334,964.
The most recent open market insider trade was Automatic Sell of 355 shares on a day where the closing price was 55. The insider, O’NEIL PATRICK R., now holds 14,452 shares of IONS.
The most recent non open market insider trade was completed by CROOKE STANLEY T on 01/15/2018, and was a acquisition of 15,893 shares with a final price of $51.76. The insider now holds 51,733 shares of Ionis Pharmaceuticals, Inc. (IONS).Examining Institutional Ownership at Ionis Pharmaceuticals, Inc. (NASDAQ:IONS)
According to Ionis Pharmaceuticals, Inc.’s latest 13F filing with the US Securities and Exchange Commission (SEC), institutional ownership is at 91.36%. The total amount of shares outstanding is 126.72 million, giving the company a market capitalization of about 5.92 billion.
There are 337 institutional holders with active positions, accounting for 114.01 million shares in total. Of those holders, 141 had increased positions amounting to 5.88 million shares, 140 had decreased positions amounting to 3.48 million shares, and 56 holders have a held position accounting for 104.65 million shares.
The top 5 institutional holders, in ascending order, are as follows: FMR LLC with 18.65 million shares, CLEARBRIDGE INVESTMENTS, LLC with 11.44 million shares, WELLINGTON MANAGEMENT GROUP LLP with 11.42 million shares, VANGUARD GROUP INC with 9.94 million shares, and BB BIOTECH AG with 7.86 million shares.
According to Ionis Pharmaceuticals, Inc. (IONS) most recent 13F filing, the company has 50 new institutional holders – accounting for 1.67 million shares of its common stock. There were 36 sold out positions, amounting to 744,905 shares.